Lymphatic Endothelial Cell Activation and Dendritic Cell Transmigration Is Modified by Genetic Deletion of Clever-1.
dendritic cells
immunosuppression
lymphatic vessels
lymphatics
migration
traffic
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
09
2020
accepted:
06
01
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
24
6
2021
Statut:
epublish
Résumé
Clever-1 also known as Stabilin-1 and FEEL-1 is a scavenger molecule expressed on a subpopulation of anti-inflammatory macrophages and lymphatic endothelial cells (LECs). However, its role in regulating dendritic cell (DC) trafficking and subsequent effects on immunity have remained unexplored. In this study, we demonstrate that DC trafficking from the skin into the draining lymph nodes is compromised in the absence of Clever-1. By adoptive transfer approaches we further show that the poor trafficking is due to the impaired entrance of DCs into afferent lymphatics. Despite this, injections of ovalbumin-loaded DCs into the footpads induced a stronger proliferative response of OT II T cells in the draining lymph nodes. This could be explained by the increased MHC II expression on DCs and a less tolerogenic phenotype of LECs in lymph nodes of Clever-1 knockout mice. Thus, although fewer DCs reach the nodes, they are more active in creating antigen-specific immune responses. This suggests that the DCs migrating to the draining lymph node within Clever-1 positive lymphatics experience immunosuppressive interactions with LECs. In conclusion, besides being a trafficking molecule on lymphatic vasculature Clever-1 is immunosuppressive towards migrating DCs and thus, regulates the magnitude of immune responses created by incoming DCs in the draining lymph nodes.
Identifiants
pubmed: 33746947
doi: 10.3389/fimmu.2021.602122
pmc: PMC7970002
doi:
Substances chimiques
Cell Adhesion Molecules, Neuronal
0
Stab1 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
602122Informations de copyright
Copyright © 2021 Tadayon, Dunkel, Takeda, Eichin, Virtakoivu, Elima, Jalkanen and Hollmén.
Déclaration de conflit d'intérêts
MH and SJ own stocks of Faron Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunity. 2012 Jun 29;36(6):1031-46
pubmed: 22749353
J Biol Chem. 2002 Sep 13;277(37):34264-70
pubmed: 12077138
J Immunol. 2008 Mar 1;180(5):3028-37
pubmed: 18292525
J Cell Mol Med. 2006 Jul-Sep;10(3):635-49
pubmed: 16989725
Nat Rev Immunol. 2020 Sep;20(9):566-578
pubmed: 32094869
J Immunol. 2016 Jan 1;196(1):115-23
pubmed: 26608916
J Biol Chem. 2003 Apr 11;278(15):12613-7
pubmed: 12473645
J Clin Cell Immunol. 2014;5:
pubmed: 25580369
Front Immunol. 2019 Mar 22;10:520
pubmed: 30967863
Nat Rev Immunol. 2012 Nov;12(11):762-73
pubmed: 23018291
Front Immunol. 2017 Feb 06;8:83
pubmed: 28220121
Clin Cancer Res. 2019 Jun 1;25(11):3289-3303
pubmed: 30755440
Annu Rev Immunol. 2017 Apr 26;35:31-52
pubmed: 27860528
Semin Immunopathol. 2014 Mar;36(2):261-74
pubmed: 24402708
Front Immunol. 2019 Mar 14;10:471
pubmed: 30923528
Adv Drug Deliv Rev. 2017 May 15;114:43-59
pubmed: 28694027
J Immunol Methods. 1999 Feb 1;223(1):77-92
pubmed: 10037236
Nature. 2008 May 1;453(7191):51-5
pubmed: 18451854
Gastroenterology. 1997 Jan;112(1):163-73
pubmed: 8978355
Sci Rep. 2016 Oct 19;6:35002
pubmed: 27756896
Nat Commun. 2020 Jan 27;11(1):538
pubmed: 31988323
Sci Immunol. 2019 Mar 29;4(33):
pubmed: 30926591
Cancer Res. 2013 Jan 1;73(1):395-405
pubmed: 23108143
Cancer Res. 2003 Aug 1;63(15):4671-6
pubmed: 12907648
Clin Cancer Res. 2014 Dec 15;20(24):6452-64
pubmed: 25320356
Sci Rep. 2014 Aug 12;4:6030
pubmed: 25112380
Front Immunol. 2017 Jan 11;7:691
pubmed: 28123388
Eur J Immunol. 2011 Jul;41(7):2052-63
pubmed: 21480214
J Immunol. 2002 Mar 15;168(6):3079-87
pubmed: 11884482
J Exp Med. 2010 Apr 12;207(4):681-8
pubmed: 20308365
Immunol Rev. 2013 Nov;256(1):240-54
pubmed: 24117825
Nat Commun. 2017 Dec 11;8(1):2034
pubmed: 29229919
Oncotarget. 2016 Jun 28;7(26):39421-39435
pubmed: 27270646
J Clin Invest. 2011 Feb;121(2):703-14
pubmed: 21293057
J Immunol. 2014 Jun 1;192(11):5002-11
pubmed: 24795456
Eur J Immunol. 2003 Mar;33(3):815-24
pubmed: 12616502
Adv Immunol. 2013;120:51-68
pubmed: 24070380
J Cell Sci. 2009 Sep 15;122(Pt 18):3365-73
pubmed: 19726632
Blood. 2004 Dec 15;104(13):3849-57
pubmed: 15297319